Literature DB >> 25746543

Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction.

Domenico Scrutinio1, Piergiuseppe Agostoni, Loreto Gesualdo, Ugo Corrà, Alessandro Mezzani, Massimo Piepoli, Andrea Di Lenarda, Annamaria Iorio, Claudio Passino, Damiano Magrì, Daniele Masarone, Elisa Battaia, Davide Girola, Federica Re, Gaia Cattadori, Gianfranco Parati, Gianfranco Sinagra, Giovanni Quinto Villani, Giuseppe Limongelli, Giuseppe Pacileo, Marco Guazzi, Marco Metra, Maria Frigerio, Mariantonietta Cicoira, Chiara Minà, Gabriella Malfatto, Sergio Caravita, Maurizio Bussotti, Elisabetta Salvioni, Fabrizio Veglia, Michele Correale, Angela B Scardovi, Michele Emdin, Pantaleo Giannuzzi, Paola Gargiulo, Marta Giovannardi, Pasquale Perrone-Filardi, Rosa Raimondo, Roberto Ricci, Stefania Paolillo, Stefania Farina, Romualdo Belardinelli, Andrea Passantino, Rocco La Gioia.   

Abstract

BACKGROUND: Chronic kidney disease is associated with sympathetic activation and muscle abnormalities, which may contribute to decreased exercise capacity. We investigated the correlation of renal function with peak exercise oxygen consumption (V̇O2) in heart failure (HF) patients. METHODS AND 
RESULTS: We recruited 2,938 systolic HF patients who underwent clinical, laboratory, echocardiographic and cardiopulmonary exercise testing. The patients were stratified according to estimated glomerular filtration rate (eGFR). Mean follow-up was 3.7 years. The primary outcome was a composite of cardiovascular death and urgent heart transplantation at 3 years. On multivariable regression, eGFR was predictor of peakV̇O2(P<0.0001). Other predictors were age, sex, body mass index, HF etiology, NYHA class, atrial fibrillation, resting heart rate, B-type natriuretic peptide, hemoglobin, and treatment. After adjusting for significant covariates, the hazard ratio for primary outcome associated with peakV̇O2<12 ml·kg(-1)·min(-1)was 1.75 (95% confidence interval (CI): 1.06-2.91; P=0.0292) in patients with eGFR ≥60, 1.77 (0.87-3.61; P=0.1141) in those with eGFR of 45-59, and 2.72 (1.01-7.37; P=0.0489) in those with eGFR <45 ml·min(-1)·1.73 m(-2). The area under the receiver-operating characteristic curve for peakV̇O2<12 ml·kg(-1)·min(-1)was 0.63 (95% CI: 0.54-0.71), 0.67 (0.56-0.78), and 0.57 (0.47-0.69), respectively. Testing for interaction was not significant.
CONCLUSIONS: Renal dysfunction is correlated with peakV̇O2. A peakV̇O2cutoff of 12 ml·kg(-1)·min(-1)offers limited prognostic information in HF patients with more severely impaired renal function.

Entities:  

Mesh:

Year:  2015        PMID: 25746543     DOI: 10.1253/circj.CJ-14-0806

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  10 in total

Review 1.  Redefining biomarkers in heart failure.

Authors:  Michele Correale; Ilenia Monaco; Natale Daniele Brunetti; Matteo Di Biase; Marco Metra; Savina Nodari; Javed Butler; Mihi Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

Review 2.  [Cardio-renal axis : Relationship of heart failure and renal insufficiency as comorbidities].

Authors:  M Zeisberg; M J Koziolek
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

3.  Predictors of improvements in exercise capacity during cardiac rehabilitation in the recovery phase after coronary artery bypass graft surgery versus acute myocardial infarction.

Authors:  Yuji Suzuki; Kenichi Ito; Kazuya Yamamoto; Noriyuki Fukui; Hidetoshi Yanagi; Kazufumi Kitagaki; Harumi Konishi; Tetsuo Arakawa; Michio Nakanishi; Yoichi Goto
Journal:  Heart Vessels       Date:  2017-11-08       Impact factor: 2.037

Review 4.  The impact of exercise on physical function, cardiovascular outcomes and quality of life in chronic kidney disease patients: a systematic review.

Authors:  Baris Afsar; Dimitrie Siriopol; Gamze Aslan; Ozgur C Eren; Tuncay Dagel; Ugur Kilic; Asiye Kanbay; Alexandru Burlacu; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-01-17       Impact factor: 2.370

5.  Determinants of maximal oxygen uptake in patients with heart failure.

Authors:  Javier Roibal Pravio; Eduardo Barge Caballero; Cayetana Barbeito Caamaño; Maria Jesus Paniagua Martin; Gonzalo Barge Caballero; David Couto Mallon; Patricia Pardo Martinez; Zulaika Grille Cancela; Paula Blanco Canosa; Jose Manuel García Pinilla; Jose Manuel Vázquez Rodríguez; Maria Generosa Crespo Leiro
Journal:  ESC Heart Fail       Date:  2021-03-27

Review 6.  Exercise and heart failure: an update.

Authors:  Gaia Cattadori; Chiara Segurini; Anna Picozzi; Luigi Padeletti; Claudio Anzà
Journal:  ESC Heart Fail       Date:  2017-12-13

7.  Effects of 12-Week Low or Moderate Dietary Acid Intake on Acid-Base Status and Kidney Function at Rest and during Submaximal Cycling.

Authors:  Enni-Maria Hietavala; Johanna K Ihalainen; Lynda A Frassetto; Moritz Schumann; Daniela Eklund; Hannu Pitkänen; Keijo Häkkinen; Antti A Mero
Journal:  Nutrients       Date:  2018-03-08       Impact factor: 5.717

8.  The MECKI score initiative: Development and state of the art.

Authors:  Elisabetta Salvioni; Alice Bonomi; Federica Re; Massimo Mapelli; Irene Mattavelli; Giuseppe Vitale; Filippo M Sarullo; Pietro Palermo; Fabrizio Veglia; Piergiuseppe Agostoni
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

Review 9.  Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid.

Authors:  Andrea Tedeschi; Piergiuseppe Agostoni; Beatrice Pezzuto; Ugo Corra'; Domenico Scrutinio; Rocco La Gioia; Rosa Raimondo; Andrea Passantino; Massimo F Piepoli
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

10.  Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers.

Authors:  Gaia Cattadori; Silvia Di Marco; Stefania Farina; Giuseppe Limongelli; Emanuele Monda; Roberto Badagliacca; Silvia Papa; Lucia Tricarico; Michele Correale
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.